Want to see GKOS full AI Analyst Report?
GKOS Stock Chart & Stats
$153.58
-$1.67(-1.09%)
At close: 4:00 PM EDT
$153.58
-$1.67(-1.09%)
Day’s Range― - ―
52-Week Range$73.16 - $184.00
Previous Close$151.91
Volume727.53K
Average Volume (3M)743.16K
Market Cap
$9.83B
Enterprise Value$8.04K
Total Cash (Recent Filing)$286.23M
Total Debt (Recent Filing)$102.84M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Nov 04, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.25
Shares Outstanding58,983,936
10 Day Avg. Volume492,926
30 Day Avg. Volume743,158
Financial Highlights & Ratios
PEG Ratio-1.87
Price to Book (P/B)9.84
Price to Sales (P/S)12.73
P/FCF Ratio-119.57
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$186.92Price Target Upside21.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$630.02M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue Growth & High MarginsStrong top-line growth coupled with consistently high gross margins indicates durable product economics and operating leverage potential. Over the next several months, this supports continued reinvestment in commercial expansion while preserving unit profitability if volume trends persist.
Product Leadership & Deep PipelineiDose TR adoption, robust clinical evidence and a multi-program pipeline create sustainable competitive advantages. Regulatory wins (re‑administration) and multi-year implant economics can foster repeatable procedure demand and durable surgeon preference over the coming months to years.
Improved Leverage & Asset BaseMarked improvement in leverage increases financial flexibility and reduces interest burden risk. A stronger balance sheet and sizable asset base support continued R&D and commercial investment without immediate refinancing pressure, improving resilience over the next 2–6 months.
Bears Say
Negative Cash Flow & LossesDespite narrowing burn, persistent negative free cash flow and ongoing net losses mean the business is not yet self‑funding. Reliance on external capital or operating improvements remains necessary to sustain growth investments, a structural constraint until consistent positive cash generation is achieved.
Reimbursement & LCD UncertaintyProcedural pharmaceuticals and devices depend on favorable payer coverage. Uncertain LCD outcomes and potential restrictive provisions are durable risks that can slow adoption, constrain physician uptake and depress realized revenues until coverage clarity is achieved across major payers.
High Operating Spend & Reinvestment NeedsLarge planned OpEx and stepped-up R&D are necessary to commercialize pipeline but compress near-term profitability. This structural cost base requires sustained revenue execution to reach break‑even and can extend the timeline to durable profitability if growth underperforms expectations.
Glaukos News
GKOS FAQ
What was Glaukos’s price range in the past 12 months?
Glaukos lowest stock price was $73.16 and its highest was $184.00 in the past 12 months.
What is Glaukos’s market cap?
Glaukos’s market cap is $9.83B.
When is Glaukos’s upcoming earnings report date?
Glaukos’s upcoming earnings report date is Nov 04, 2026 which is in 90 days.
How were Glaukos’s earnings last quarter?
Glaukos released its earnings results on Jul 29, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.211 by $0.071.
Is Glaukos overvalued?
According to Wall Street analysts Glaukos’s price is currently Undervalued.
Does Glaukos pay dividends?
Glaukos does not currently pay dividends.
What is Glaukos’s EPS estimate?
Glaukos’s EPS estimate is -0.1.
How many shares outstanding does Glaukos have?
Glaukos has 58,983,936 shares outstanding.
What happened to Glaukos’s price movement after its last earnings report?
Glaukos reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.211. Following the earnings report the stock price went up 4.243%.
Which hedge fund is a major shareholder of Glaukos?
Currently, no hedge funds are holding shares in GKOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Glaukos Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$186.92 (21.71% Upside)
$186.92 (21.71% Upside)
Blogger Sentiment
Bearish
GKOS Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 319.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 12.6%
Last 30 Days ▲ 30.3%
Last 30 Days ▲ 30.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.54%
Trailing 12-Months
Company Description
Glaukos
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
GKOS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a strongly positive operational and financial picture driven by record Q2 sales, raised full-year guidance, robust iDose TR adoption, promising early Epioxa traction and a deep clinical pipeline. Near-term risks are primarily transitional and execution-related: Epioxa J-code operationalization, potential LCD/reimbursement outcomes, international competitive dynamics and expected FX headwinds. Management is taking a conservative posture on Q3 cadence while continuing disciplined reinvestment and expects margin accretion and path to profitability over time.View all GKOS earnings summariesGKOS Stock 12 Month Forecast
Average Price Target
$186.92
▲(21.71% Upside)
Technical Analysis
Integer Holdings
―
Ufp Technologies
―
Tandem Diabetes Care
―
LivaNova
―
Irhythm Technologies
―
Ownership Overview
3.89% Insiders
37.75% Mutual Funds
2.75% Other Institutional Investors
30.78% Public Companies and
Individual Investors